Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Gemcitabine, Etoposide, Dexamethasone and Pegaspargase Chemotherapy (GELAD) With Sandwiched Radiotherapy in the Treatment of Stage IE/II Natural Killer/T-Cell Lymphoma: A Multicenter, Prospective Study

NCT02733458 is registered in ClinicalTrials.gov with Xinhua Hospital, Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT02733458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02733458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Gemcitabine, Etoposide, Dexamethasone and Pegaspargase Chemotherapy (GELAD) With Sandwiched Radiotherapy in the Treatment of Stage IE/II Natural Killer/T-Cell Lymphoma: A Multicenter, Prospective Study
Lead sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Not applicable
Overall status
Completed
Start date
March 31, 2016
Completion date
April 30, 2021
Enrollment
52 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

extranodal nk-t-cell lymphoma, nasal type